Evidence map›Paper›PMID 36975888›Full record

ArticleJournal of cardiovascular development and disease2023

Impact of Mitral Regurgitation Recurrence on Mitral Valve Repair for Secondary Ischemic Mitral Regurgitation.

Antonio Salsano, Antonio Nenna, Nicolas Molinari, Sanjeet Singh Avtaar Singh, Cristiano Spadaccio, Francesco Santini, Massimo Chello, Antonio Fiore, Francesco Nappi

Open access · goldAbstract read
In one paragraph

Article in Journal of cardiovascular development and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 4 countries.

Antonio SalsanoDISC Department, University of Genoa, 16132 Genova, Italy.ORCID 0000-0002-2047-8373
Antonio NennaDepartment of Cardiovascular Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.ORCID 0000-0002-4069-6781
Nicolas MolinariIDESP, INSERM, PreMEdical INRIA, University of Montpellier, CHU Montpellier, 34295 Montpellier, France.
Sanjeet Singh Avtaar SinghCardiothoracic Surgery, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, UK.ORCID 0000-0003-4320-0734
Cristiano SpadaccioDepartment of Cardiovascular Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Francesco SantiniDISC Department, University of Genoa, 16132 Genova, Italy.
Massimo ChelloDepartment of Cardiovascular Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.ORCID 0000-0001-8178-7068
Antonio FioreDepartment of Cardiac Surgery, Hôpitaux Universitaires Henri Mondor APHP, 94000 Creteil, France.ORCID 0000-0001-7962-7276
Francesco NappiCardiac Surgery, Centre Cardiologique du Nord de Saint-Denis, 93200 Paris, France.ORCID 0000-0002-9705-5360
Università Campus Bio-Medico · ITUniversity of Genoa · ITCentre Cardiologique du Nord · FREdinburgh Royal Infirmary · GBHôpitaux Universitaires Henri-Mondor · FRInstitut national de recherche en sciences et technologies du numérique · FRMayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe current guidelines still do not include specific recommendations on the use of subvalvular repair (SV-r) for treatment of ischemic mitral regurgitation (IMR). Therefore, the objective of our study was to evaluate the clinical impact of mitral regurgitation (MR) recurrence and ventricular remodeling on long-term outcomes after SV-r combined with restrictive annuloplasty (RA-r).

methodsWe performed a subanalysis of the papillary muscle approximation trial, studying 96 patients with severe IMR and coronary artery disease undergoing restrictive annuloplasty alongside subvalvular repair (SV-r + RA-r group) or restrictive annuloplasty alone (RA-r group). We analyzed treatment failure differences, the influence of residual MR, left ventricular remodeling, and clinical outcomes. The primary endpoint was treatment failure (composite of death; reoperation; or recurrence of moderate, moderate-to-severe, or severe MR) within 5 years of follow-up after the procedure.

resultsA total of 45 patients showed failure of the treatment within 5 years, of which 16 patients underwent SV-r + RA-r (35.6%) and 29 underwent RA-r (64.4%,

conclusionsRA-r remains a surgical mitral repair technique with an increased risk of failure and mortality at 5 years compared with SV-r. The rates of recurrent MR are higher, and recurrence occurs earlier, with RA-r alone compared to SV-r. The addition of the subvalvular repair increases the durability of the repair, thus extending all of the benefits of preventing MR recurrence.

Indexed as

ischemic heart diseaseleft ventricular remodelingmitral valve repairpapillary musclesecondary mitral regurgitation

Identifiers

PMID36975888
PMCPMC10053850
OpenAlexW4327624577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.